A lack of specific and effective treatment for Type 2 diabetes has long demanded to establish a better therapeutic modality. As the maitake mushroom extract, SX-fraction (SXF), has been shown to have anti-diabetic activity, we investigated if SXF would demonstrate such an activity in diabetic KK-Ay mice. Test materials included original maitake mushroom (Orig-M), two different doses of SXF [low dose of SXF (L) and high dose of SXF (H)], and Actos? (ACT). Two hundred KK-Ay mice were divided into five experimental groups: (A) Sham (none given), (B) Orig-M, (C) SXF (L), (D) SXF (H), and (E) ACT. Mice received these materials for 8 weeks, while the experimental conditions, such as body weight and diabetic/lipid parameters, were monitored every two weeks. No significant changes in body weight were seen in all experimental groups. Regarding diabetic parameters, the serum glucose (GLC) levels in the groups B and C were significantly lower than the Sham group (A) at 2 weeks. The GLC decline was seen further in the groups C and D at 8 weeks. However, the levels of 1,5-anhydro-D-glucitol (1,5-AG), a marker used for the short-term glycemic control, showed no significant changes between the groups. The significant reduction in the serum insulin (INS) levels was yet detected in the group D at 8 weeks. Serum lipid parameters, i.e., serum triglyceride (TGL), total cholesterol (CHL), and high-density lipoprotein (HDL), in the groups (B-E) were noticeably higher than the Sham (A) group, although such differences were not statistically significant. In conclusion, SXF appears to significantly lower the GLC and INS levels in KK-Ay mice. However, no significant changes or improvements in lipid parameters (TGL, CHL, and HDL) were found with SXF. Nonetheless, this study demonstrates that SXF has anti-diabetic activity, capable of improving certain diabetic conditions.
References
[1]
Khan, M.A.B., Hashim, M.J., King, J.K., Govender, R.D., Mustafa, H. and Al Kaabi, J. (2020) Epidemiology of Type 2 Diabetes—Global Burden of Disease and Forecasted Trends. Journal of Epidemiology and Global Health, 10, 107-111. https://doi.org/10.2991/jegh.k.191028.001
[2]
Alper, J. (2000) New Insights into Type 2 Diabetes. Science, 289, 37-39. https://doi.org/10.1126/science.289.5476.37
[3]
Wagman, A.S. and Nuss, J.M. (2001) Current Therapies and Emerging Targets for the Treatment of Diabetes. CurrentPharmaceuticalDesign, 7, 417-450. https://doi.org/10.2174/1381612013397915
[4]
Tiwari, D., Loh, W.J. and Aw, T.C. (2025) Updates from the 2025 American Diabetes Association Guidelines on Standards of Medical Care in Diabetes. ExplorationofEndocrineandMetabolicDiseases, 2, Article 101428. https://doi.org/10.37349/eemd.2025.101428
[5]
American Diabetes Association (ADA) (2012) Standards of Medical Care in Diabetes 2011. Diabetes Care, 34, S11-S63.
[6]
Deshpande, A.D., Harris-Hayes, M. and Schootman, M. (2008) Epidemiology of Diabetes and Diabetes-Related Complications. Physical Therapy, 88, 1254-1264. https://doi.org/10.2522/ptj.20080020
[7]
Caro, J.F. (1990) Effects of Glyburide on Carbohydrate Metabolism and Insulin Action in the Liver. The American Journal of Medicine, 89, S17-S25. https://doi.org/10.1016/0002-9343(90)90332-8
[8]
Groop, L.C. (1999) Insulin Resistance: The Fundamental Trigger of Type 2 Diabetes. Diabetes, Obesity and Metabolism, 1, S1-S7. https://doi.org/10.1046/j.1463-1326.1999.0010s1001.x
[9]
Nolan, J.J., Ludvik, B., Beerdsen, P., Joyce, M. and Olefsky, J. (1994) Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone. NewEnglandJournalofMedicine, 331, 1188-1193. https://doi.org/10.1056/nejm199411033311803.
[10]
DeFronzo, R.A. and Goodman, A.M. (1995) Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine, 333, 541-549. https://doi.org/10.1056/nejm199508313330902
[11]
Kubo, K., Aoki, H. and Nanba, H. (1994) Anti-Diabetic Activity Present in the Fruit Body of Grifola frondosa (Maitake). I. Biological and Pharmaceutical Bulletin, 17, 1106-1110. https://doi.org/10.1248/bpb.17.1106
[12]
Manohar, V., Talpur, N.A., Echard, B.W., Lieberman, S. and Preuss, H.G. (2002) Effects of a Water-Soluble Extract of Maitake Mushroom on Circulating Glucose/Insulin Concentrations in KK Mice. Diabetes, Obesity and Metabolism, 4, 43-48. https://doi.org/10.1046/j.1463-1326.2002.00180.x
[13]
Preuss, H.G., Echard, B., Bagchi, D., Perricone, N.V. and Zhuang, C. (2007) Enhanced Insulin-Hypoglycemic Activity in Rats Consuming a Specific Glycoprotein Extracted from Maitake Mushroom. Molecular and Cellular Biochemistry, 306, 105-113. https://doi.org/10.1007/s11010-007-9559-6
[14]
Mizuno, T. and Zhuang, C. (1995) Maitake, Grifola frondosa: Pharmacological Effects. Food Reviews International, 11, 135-149. https://doi.org/10.1080/87559129509541024
[15]
Adachi, K., Nanba, H. and Kuroda, H. (1987) Potentiation of Host-Mediated Antitumor Activity in Mice by-Glucan Obtained from Grifola frondosa (Maitake). ChemicalandPharmaceuticalBulletin, 35, 262-270. https://doi.org/10.1248/cpb.35.262
[16]
National Cancer Institute (1992) Developmental Therapeutics Program. In-Vitro Anti-HIV Drug Screening Results (National Science Council F195001).
[17]
Maitake Products Inc (1998) D-Fraction Obtained IND for Clinical Study (Corporate Publication).
[18]
Tomino, Y. (2012) Lessons from the Kk-Ay Mouse, a Spontaneous Animal Model for the Treatment of Human Type 2 Diabetic Nephropathy. Nephro-Urology Monthly, 4, 524-529. https://doi.org/10.5812/numonthly.1954
[19]
Okazaki, M., Saito, Y., Udaka, Y., Maruyama, M., Murakami, H., Ota, S., et al. (2002) Diabetic Nephropathy in KK and KK-Ay Mice. Experimental Animals, 51, 191-196. https://doi.org/10.1538/expanim.51.191
[20]
Griggs, R.B., Donahue, R.R., Adkins, B.G., Anderson, K.L., Thibault, O. and Taylor, B.K. (2016) Pioglitazone Inhibits the Development of Hyperalgesia and Sensitization of Spinal Nociresponsive Neurons in Type 2 Diabetes. The Journal of Pain, 17, 359-373. https://doi.org/10.1016/j.jpain.2015.11.006
[21]
Yamanouchi, T. and Akanuma, Y. (1994) Serum 1,5-Anhydroglucitol (1,5 AG): New Clinical Marker for Glycemic Control. Diabetes Research and Clinical Practice, 24, S261-S268. https://doi.org/10.1016/0168-8227(94)90259-3
[22]
Wong, N.D. and Sattar, N. (2023) Cardiovascular Risk in Diabetes Mellitus: Epidemiology, Assessment and Prevention. Nature Reviews Cardiology, 20, 685-695. https://doi.org/10.1038/s41569-023-00877-z
[23]
Dungan, K.M. (2008) 1,5-Anhydroglucitol (GlycoMark) as a Marker of Short-Term Glycemic Control and Glycemic Excursions. Expert Review of Molecular Diagnostics, 8, 9-19. https://doi.org/10.1586/14737159.8.1.9
[24]
Buse, J.B., Freeman, J.L.R., Edelman, S.V., Jovanovic, L. and McGill, J.B. (2003) Serum 1,5-Anhydroglucitol (GlycoMark): A Short-Term Glycemic Marker. Diabetes Technology & Therapeutics, 5, 355-363. https://doi.org/10.1089/152091503765691839
[25]
Cen, H.H., Hussein, B., Botezelli, J.D., Wang, S., Zhang, J.A., Noursadeghi, N., et al. (2022) Human and Mouse Muscle Transcriptomic Analyses Identify Insulin Receptor mRNA Downregulation in Hyperinsulinemia-Associated Insulin Resistance. The FASEB Journal, 36, e22088. https://doi.org/10.1096/fj.202100497rr
[26]
Morita, I., Tanimoto, K., Akiyama, N., Naya, N., Fujieda, K., Iwasaki, T., et al. (2017) Chronic Hyperinsulinemia Contributes to Insulin Resistance under Dietary Restriction in Association with Altered Lipid Metabolism in Zucker Diabetic Fatty Rats. American Journal of Physiology-Endocrinology and Metabolism, 312, E264-E272. https://doi.org/10.1152/ajpendo.00342.2016
[27]
Liu, C.H., Lee, T.H., Lin, Y.S., Sung, P.S., Wei, Y.C. and Li, Y.R. (2020) Pioglitazone and PPAR-Modulating Treatment in Hypertensive and Type 2 Diabetic Patients after Ischemic Stroke: A National Cohort Study. CardiovascularDiabetology, 19, Article No. 2. https://doi.org/10.1186/s12933-019-0979-x
[28]
Lawrence, J.M. and Reckless, J.P.D. (2001) Actos (Pioglitazone): A New Treatment for Type 2 Diabetes. HospitalMedicine, 62, 411-416. https://doi.org/10.12968/hosp.2001.62.7.1611
[29]
Konno, S., Alexander, B., Zade, J. and Choudhury, M. (2013) Possible Hypoglycemic Action of SX-Fraction Targeting Insulin Signal Transduction Pathway. InternationalJournalofGeneralMedicine, 6, 181-187. https://doi.org/10.2147/ijgm.s41891
[30]
Saltiel, A.R. and Kahn, C.R. (2001) Insulin Signalling and the Regulation of Glucose and Lipid Metabolism. Nature, 414, 799-806. https://doi.org/10.1038/414799a
[31]
Khalid, M., Alkaabi, J., Khan, M.A.B. and Adem, A. (2021) Insulin Signal Transduction Perturbations in Insulin Resistance. International Journal of Molecular Sciences, 22, Article 8590. https://doi.org/10.3390/ijms22168590